文献速递骨质疏松与代谢性骨病

地舒单抗的疗效、安全性、持续性与序贯策略:系统综述

Denosumab-efficacy, safety, persistence and sequential strategies-a systematic review.
PubMed 文献 · Osteoporos Int · 2026-10-02

该研究于2025年9月22日检索多个数据库,纳入71项随机对照试验和观察性研究,系统评价地舒单抗治疗骨质疏松的疗效、安全性、持续性及停药后序贯治疗策略。结果显示地舒单抗在提升骨密度和降低骨折风险方面优于双膦酸盐,但停药可导致骨转换指标快速反弹、骨密度下降和椎体骨折风险增加,需长期规划并适时启动序贯治疗。

要点

  • 地舒单抗提升骨密度和降低椎体及非椎体骨折风险优于双膦酸盐。
  • 停药后骨转换指标快速升高、骨密度下降,椎体骨折风险增加。
  • 口服或静脉双膦酸盐序贯治疗可减轻但未完全防止骨丢失和骨转换反弹。

核心结论

  • 地舒单抗是有效的骨质疏松治疗药物,在改善骨密度方面优于双膦酸盐且与促骨形成治疗相当,在降低骨折风险方面优于双膦酸盐。
  • 停药带来临床显著的骨丢失和椎体骨折风险,需长期治疗规划并及时启动适当序贯治疗以优化患者结局。

研究设计与样本

  • 系统综述,检索Embase、PubMed和Cochrane Library,检索日期为2025年9月22日。
  • 纳入评估地舒单抗疗效、安全性、持续性及停药后序贯治疗临床结局的随机对照试验和观察性研究。
  • 共纳入71项研究,数据提取和质量评价由两名作者独立按照PRISMA指南进行。
  • 地舒单抗与安慰剂及双膦酸盐的疗效通过相关试验的荟萃分析评估,其余结局采用叙述性综合描述。

主要发现

  • 与安慰剂相比,地舒单抗持续增加骨密度、降低骨转换标志物,并降低椎体和非椎体骨折风险。
  • 与双膦酸盐相比,地舒单抗通常带来更大的骨密度增益和更优的骨折结局。
  • 地舒单抗对骨密度的变化与特立帕肽相当,而罗莫佐单抗在腰椎带来更大增益。
  • 比较地舒单抗与促骨形成治疗时,无骨折风险数据可用。
  • 真实世界研究通常报告地舒单抗短期持续性和依从性高,但长期随访中治疗持续性下降。

关键数值与推荐

  • 与安慰剂相比,地舒单抗持续增加骨密度、降低骨转换标志物并降低椎体和非椎体骨折风险。
  • 与双膦酸盐相比,地舒单抗通常带来更大骨密度增益和更优骨折结局。
  • 地舒单抗对骨密度的变化与特立帕肽相当,罗莫佐单抗在腰椎带来更大增益。
  • 停用地舒单抗与骨转换标志物快速升高、骨密度增益丢失和椎体骨折风险增加相关。
  • 口服或静脉双膦酸盐序贯治疗可减轻但未完全防止骨转换 overshoot 和骨丢失。

临床怎么用

  • 地舒单抗治疗需长期规划,停药时应及时启动适当序贯治疗以降低骨丢失和椎体骨折风险。
  • 口服或静脉双膦酸盐可作为序贯治疗选择,但需注意其不能完全防止骨转换反弹和骨丢失。
  • 真实世界长期治疗持续性下降,需关注患者依从性并加强随访管理。

局限性

  • 比较地舒单抗与促骨形成治疗时无骨折风险数据可用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Denosumab (DMAB), a monoclonal antibody targeting receptor activator of nuclear factor kappa-Β ligand (RANKL), is an effective antiresorptive therapy for osteoporosis that increases bone mineral density (BMD) and reduces the risk of vertebral and non-vertebral fractures. However, its effects are rapidly reversible, and treatment delays or discontinuation are associated with bone turnover overshoot, loss of BMD, and an increased risk of vertebral fractures. Despite generally high treatment persistence, DMAB is frequently discontinued, necessitating appropriate sequential therapy to prevent overshoot in bone turnover. This review summarizes the literature on the efficacy, safety, and persistence of DMAB treatment, as well as strategies for transitioning to other anti-osteoporosis therapies after discontinuation. METHODS: A literature search was conducted on September 22, 2025, across multiple databases, including Embase, PubMed, and the Cochrane Library. Randomized controlled trials (RCTs) and observational studies evaluating the efficacy, safety, and persistence of DMAB, as well as clinical outcomes following DMAB discontinuation and subsequent sequential therapy, were included. Data extraction and quality assessment were conducted independently by two authors in accordance with PRISMA guidelines. The efficacy of DMAB compared with placebo and bisphosphonates (BPs) was assessed by meta-analyses of the relevant trials. The remaining outcomes were assessed and described using a narrative synthesis. RESULTS: A total of 71 studies met the inclusion criteria. Compared with placebo, DMAB consistently increased BMD, reduced BTMs, and lowered the risk of vertebral and non-vertebral fractures. Across included studies, DMAB generally resulted in greater BMD gains and improved fracture outcomes compared with BPs. Changes in BMD were comparable to those observed with teriparatide, while romosozumab resulted in larger gains in the lumbar spine. No data was available on fracture risk when comparing DMAB to osteoanabolic therapies. Real-world studies generally reported high short-term persistence and compliance with DMAB, but treatment persistence declined over longer follow-up periods. Discontinuation of DMAB was associated with rapid increases in BTMs, loss of BMD gains, and an increased risk of vertebral fractures. Sequential treatment with oral or IV BPs attenuated but did not completely prevent bone turnover overshoot and bone loss. CONCLUSION: DMAB is an effective treatment for osteoporosis, superior to BPs and comparable to anabolic treatments in improving BMD and superior to BPs in reducing fracture risk, but its discontinuation carries clinically significant risks of bone loss and vertebral fractures. Consequently, discontinuing DMAB requires long-term treatment planning, and the timely initiation of appropriate sequential therapy is essential to optimize patient outcomes.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Laursen NA, Sølling AS, Harsløf T, et al. Denosumab-efficacy, safety, persistence and sequential strategies-a systematic review. Osteoporos Int. 2026. PMID: 42825930. doi:10.1007/s00198-026-08237-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。